XML 31 R22.htm IDEA: XBRL DOCUMENT

Subsequent events	9 Months Ended
Subsequent events	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent events	Subsequent events Acquisition of ChemoCentryx, Inc. On October 20, 2022, Amgen completed its acquisition of ChemoCentryx for $52.00 per share in cash, for an aggregate merger consideration of approximately $3.7 billion. ChemoCentryx is a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The accounting impact of this acquisition and the results of operations for ChemoCentryx will be included in our consolidated financial statements beginning in the fourth quarter of 2022. The initial accounting for this acquisition is incomplete, pending identification and measurement of the assets acquired and liabilities assumed. Divestiture of Gensenta İlaç Sanayi ve Ticaret A.Ş. On November 2, 2022, Amgen completed its divestiture transaction with Eczacıbaşı. The accounting impact upon completion of this divestiture will be included in our consolidated financial statements in the fourth quarter of 2022. See Note 2, Acquisitions and divestitures.